论文部分内容阅读
目的研究β受体拮抗剂在并发心血管疾病的COPD患者中运用。方法将COPD并发心血管疾病患者分为5组,分别是ICS、ICS+LABA+TIO、ICS+LABA+TIO+BB,BB,Placebo组,回顾性分析β受体拮抗剂对肺功能、血氧饱和度、病死率的影响。结果 BB治疗组,与ICS、ICS+LABA+TIO组比较,对FEV1降低不显著,有统计学意义(t=7.069,P<0.05);SpO2无统计学意义(t=3.076,P>0.05);β受体拮抗剂治疗组能有效降低病死率,总病死率降低率为18%左右(t=16.87,P<0.05)。结论β受体拮抗剂不会降低并发心血管疾病的COPD患者的FEV1,能降低其病死率。
Objective To study the use of β-receptor antagonists in patients with COPD complicated by cardiovascular diseases. Methods The patients with COPD complicated with cardiovascular diseases were divided into five groups: ICS, ICS + LABA + TIO, ICS + LABA + TIO + BB, BB and Placebo group. The effects of β- Saturation, mortality effects. Results Compared with ICS and ICS + LABA + TIO group, the decrease of FEV1 in BB group was not statistically significant (t = 7.069, P <0.05); SpO2 was not statistically significant (t = 3.076, P> 0.05) ; The treatment group of β-receptor antagonist can effectively reduce the case fatality rate, and the overall mortality rate is about 18% (t = 16.87, P <0.05). CONCLUSIONS: β-adrenergic antagonists do not reduce FEV1 in COPD patients with cardiovascular disease and reduce their mortality.